Clinical Trial Update: An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases [Phase 2]

View source ↗

Summary

Phase II open-label study investigating dacomitinib for EGFR-mutated non-small cell lung cancer with brain metastases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Dacomitinib (dacomitinib)

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases | Phase 2 | Status: UNKNOWN